Isoniazida Labesfal (Isoniazid)

Isoniazid is converted by the bacterial enzyme catalase‑peroxidase into an active metabolite that blocks the synthesis of mycolic acids, essential lipids in the mycobacterial cell wall. This inhibition weakens the wall, leading to bacterial death, especially in rapidly dividing Mycobacterium tuberculosis cells.

The dosage of Isoniazida Labesfal is determined by the prescribing clinician based on the patient’s age, weight, disease severity, and treatment protocol. Healthcare professionals follow national or WHO guidelines to select the appropriate dose and duration.

Isoniazida Labesfal is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy when the benefits outweigh potential risks, and it is generally considered compatible with breastfeeding under medical advice.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Isoniazida Labesfal (isoniazid) is a first‑line agent with high early bactericidal activity, often used in combination with rifampicin, pyrazinamide, and ethambutol. Compared with newer agents, it is inexpensive and well‑studied, but it carries a higher risk of hepatotoxicity and peripheral neuropathy, requiring monitoring and pyridoxine supplementation.

Isoniazida Labesfal should be stored at 2‑8 °C, protected from light, and kept in its original packaging to maintain stability. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to local regulations.

The product is supplied as an injectable solution for intramuscular injection. Administration is performed by a qualified healthcare professional using aseptic technique, typically into the gluteal or deltoid muscle, following the dose prescribed by the treating physician.

The most serious risks include severe hepatitis, which may present with jaundice, dark urine, and abdominal pain, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Neurological toxicity, such as seizures, can also occur, especially in overdose or in patients with pre‑existing conditions.

Isoniazida Labesfal is contraindicated in patients with known hypersensitivity to isoniazid or any component of the formulation. It should also be avoided in individuals with acute liver failure or severe hepatic impairment until a specialist determines that benefits outweigh risks.